APA (7th ed.) Citation

Luber, B., Deplazes, J., Keller, G., Walch, A., Rauser, S., Eichmann, M., . . . Lordick, F. (2011). Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: Results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC cancer, 11, . https://doi.org/10.1186/1471-2407-11-509

Chicago Style (17th ed.) Citation

Luber, Birgit, et al. "Biomarker Analysis of Cetuximab Plus Oxaliplatin/leucovorin/5-fluorouracil in First-line Metastatic Gastric and Oesophago-gastric Junction Cancer: Results from a Phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)." BMC Cancer 11 (2011). https://doi.org/10.1186/1471-2407-11-509.

MLA (9th ed.) Citation

Luber, Birgit, et al. "Biomarker Analysis of Cetuximab Plus Oxaliplatin/leucovorin/5-fluorouracil in First-line Metastatic Gastric and Oesophago-gastric Junction Cancer: Results from a Phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)." BMC Cancer, vol. 11, 2011, https://doi.org/10.1186/1471-2407-11-509.